619 related articles for article (PubMed ID: 18608587)
1. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP).
Knorr C; Melling N; Goehl J; Drachsler T; Hohenberger W; Meyer T
Int J Hyperthermia; 2008 Aug; 24(5):409-14. PubMed ID: 18608587
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities.
Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C
Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048
[TBL] [Abstract][Full Text] [Related]
3. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
[TBL] [Abstract][Full Text] [Related]
4. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities.
Papa MZ; Klein E; Karni T; Koller M; Davidson B; Azizi E; Ben-Ari G
Am J Surg; 1996 Apr; 171(4):416-20. PubMed ID: 8604833
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
[TBL] [Abstract][Full Text] [Related]
8. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion.
Noorda EM; van Kreij RH; Vrouenraets BC; Nieweg OE; Muller M; Kroon BB; Aaronson NK
Eur J Surg Oncol; 2007 Aug; 33(6):776-82. PubMed ID: 17300914
[TBL] [Abstract][Full Text] [Related]
9. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma.
Möller MG; Lewis JM; Dessureault S; Zager JS
Int J Hyperthermia; 2008 May; 24(3):275-89. PubMed ID: 18393005
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
[TBL] [Abstract][Full Text] [Related]
11. Second malignant neoplasm occurring years after hyperthermic isolated limb perfusion for melanoma.
Lenormand C; Pelletier C; Goeldel AL; Chenard MP; Grange F
Arch Dermatol; 2010 Mar; 146(3):319-21. PubMed ID: 20231505
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
[TBL] [Abstract][Full Text] [Related]
14. [Relations of chemotherapy-induced tumor necrosis to plasma platin concentration and primary tumor temperature in patients with osteosarcoma in the lower extremities treated by hyperthermic isolation limb perfusion with cisplatin].
Fan S; Yang D; Tao H; Ye Z; He R
Zhonghua Wai Ke Za Zhi; 2000 May; 38(5):336-9. PubMed ID: 11832050
[TBL] [Abstract][Full Text] [Related]
15. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma.
Kettelhack C; Kraus T; Hupp T; Manner M; Schlag P
Eur J Surg Oncol; 1990 Aug; 16(4):370-5. PubMed ID: 2379595
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic isolated regional perfusion of the limb with carboplatin.
Daryanani D; de Vries EG; Guchelaar HJ; van Weerden TW; Hoekstra HJ
Eur J Surg Oncol; 2000 Dec; 26(8):792-7. PubMed ID: 11087648
[TBL] [Abstract][Full Text] [Related]
18. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
[TBL] [Abstract][Full Text] [Related]
19. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
[TBL] [Abstract][Full Text] [Related]
20. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
